| Literature DB >> 26931063 |
Mingjie Wang1, Xudan Li1, Jianxun Zou1, Xugao Chen1, Shuyan Chen1, Wanqing Xiang1.
Abstract
BACKGROUND This study aimed to evaluate the diagnostic value of the D value, D* value, and f magnitude for identifying benign and malignant hepatic tumors using intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI). MATERIAL AND METHODS Data of 89 cases (123 lesions) with hepatic tumor confirmed by surgical pathology and postoperative follow-up were retrospectively collected. Among these cases, 40 cases were benign hepatic tumors (57 lesions) and 49 cases were malignant hepatic tumors (66 lesions). All subjects underwent conventional MRI with T1WI, T2WI, multi-b-value DWI, and dynamic enhanced LAVA scan. Diffusion-weighted images with 11 b values (0, 10, 20, 30, 50, 80, 100, 200, 400, 800, and 1000 s/mm2) were obtained to calculate true molecular diffusion (D), perfusion-related diffusion coefficient (D*), and perfusion fraction (f). The diagnostic performance in differentiating between malignant and benign hepatic lesions was analyzed. RESULTS Malignant lesions had a significantly lower D value ([1.04±0.34]×10-3 mm2/s) and D* value ([16.5±7.7]×10-3 mm2/s) compared to benign lesions (D value: [1.70±0.55]×10-3 mm2/s, P<0.01; D* value: [21.7±9.9]×10-3 mm2/s, P<0.01). There was no statistically significant difference in f values between malignant (23.3±9.5) and benign lesions (33.5±14.9, P=0.13). In addition, D exhibited a better diagnostic performance than D* in terms of the area under the curve, sensitivity, and specificity when identifying malignancies from benign lesions. CONCLUSIONS D and D* are significant parameters for diagnosing hepatic tumors. Moreover, the D value is a more reliable parameter in distinguishing benign and malignant hepatic tumors.Entities:
Mesh:
Year: 2016 PMID: 26931063 PMCID: PMC4778409 DOI: 10.12659/msm.895909
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Baseline characteristics of benign and malignant hepatic lesions.
| Benign tumors | Malignant tumors | |
|---|---|---|
| Number of patients | 40 | 49 |
| Age (years) | 43.1±6.97 | 51.2±10.6 |
| Gender ratio (Male: Female) | 23: 24 | 29: 13 |
| Lesions | 57 | 66 |
| Hemangioma (n=47) | Hepatocellular carcinoma (n=40) | |
| Hepatapostema (n=5) | Metastatic liver tumor (n=20) | |
| FNH (n=4) | Cholangiocarcinoma (n=6) | |
| Hamartoma (n=1) |
FNH – focal nodular hyperplasia.
Figure 1Plot shows In(Sb/S0) of relative signal intensity vs. b values from primary hepatocellular carcinoma. The signal attenuation curve shows a hockey-stick appearance at low b-values, which is indicative of a perfusion effect.
Figure 2A 45-year-old female patient with hepatic cavernous hemangioma. (A) Contrast-enhanced DWI during the delayed phase showing a multi-nodular enhancement on the edge of the lesion located in segment III of the liver. (B) Mapping of the signal intensity of the lesion is much higher than hepatic parenchyma when b=0 s/mm2. (C) Mapping of the estimated value of the D parameter. The average value in the lesion ROI was D=2.27×10−3 mm2/s. (D) Mapping of the estimated value of the D* parameter. The average value in the lesion ROI was D*=15.3×10−3 mm2/s. (E) Mapping of the perfusion-related diffusion fraction (f) with a value of 33.3%.
Figure 3A 63-year-old male man with primary hepatocellular carcinoma. (A) Contrast-enhanced DWI during the arterial phase showing lesion enhancement in segment IV of the liver. (B) The lesion enhancement degree in the delayed phase decreases obviously compared to that of the arterial phase. (C) The signal of the lesion is slightly higher than hepatic parenchyma when b=0 s/mm2. (D) Mapping of the estimated value of the D parameter. The average value in the lesion ROI was D=1.19×10−3 mm2/s. The signal of the lesion is slightly lower than hepatic parenchyma. (E) Mapping of the estimated value of the D* parameter. The average value in the lesion ROI was D*=22.4×10−3 mm2/s. The signal of the lesion is slightly lower than hepatic parenchyma. (F) Mapping of the perfusion-related diffusion fraction (f) with a value of 12.2%.
Comparison of IVIM Parameters between malignant and benign hepatic lesions (means ±SD).
| Benign tumors | Malignant tumors | ||
|---|---|---|---|
| D (10−3 mm2/s) | 1.70±0.55 | 1.04±0.23 | <0.01 |
| D* (10−3 mm2/s) | 21.7±9.9 | 16.5±7.7 | <0.01 |
| f (%) | 33.5±14.9 | 23.3±9.5 | 0.13 |
D – true molecular diffusion; D* – perfusion-related diffusion coefficient; f – perfusion fraction.
Diffusion parameters for all malignant tumor types among groups.
| D (10−3 mm2/s) | D* (10−3 mm2/s) | f (%) | |
|---|---|---|---|
| Hepatocellular carcinoma | 0.98±0.28 | 21.17±8.34 | 26.43±7.24 |
| Cholangiocarcinoma | 1.19±0.35 | 15.68±4.11 | 16.98±9.9 |
| Metastatic liver tumor | 0.93±0.36 | 12.22±3.71 | 21.98±8.54 |
| P values | |||
| Hepatocellular carcinoma | 0.312 | 0.342 | |
| Hepatocellular carcinoma | 0.409 | 0.987 | |
| Cholangiocarcinoma | 0.634 | ||
P<0.05 vs. cholangiocarcinoma;
P<0.05 vs. metastatic liver tumor;
D – true molecular diffusion; D* – perfusion-related diffusion coefficient; f – perfusion fraction.
Diagnostic performance for distinguishing between malignant and benign hepatic lesions.
| D | D* | ||
|---|---|---|---|
| AUC (95% CI) | 0.98 (0.94–1.00) | 0.884 (0.81–0.91) | <0.05 |
| Cut-off values (10−3 mm2/s) | 1.295 | 21.85 | |
| Sensitivity | 96.2% | 90.6% | |
| Specificity | 91.4% | 82.9% |
AUC – area under the curve; D – true molecular diffusion; D* – perfusion-related diffusion coefficient.